Salivary Oxytocin Reactivity Investigated as Biomarker for MDD Psychedelic Treatment Response
Salivary Oxytocin as a Biomarker of Psychedelic Treatment
Abstract
Study aims to investigate salivary oxytocin reactivity during psychedelic sessions as a predictor for MDD treatment response.